Active Surveillance for Low-Risk Cancer-The Waiting Is the Hardest Part

JAMA Oncol. 2024 Nov 1;10(11):1491-1492. doi: 10.1001/jamaoncol.2024.2667.
No abstract available

Plain language summary

This Viewpoint describes the benefits and challenges of active surveillance as a clinical approach to monitor low-risk cancers with favorable prognoses.